Health DiagnosticsCentral Nervous SystemBiomedical EngineeringCardiovascularNeurologyInjection MoldingSurgeryNeuroscienceBiotechnologyDeveloper PlatformMedical Device
Description
Penumbra, Inc. operates as a thrombectomy company, focused on developing innovative therapies.
The company’s broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, s…
Analysis
Hope premium
Penumbra, Inc. carries what we call a hope premium: an average business trading at an ambitious price. One caution: reported profits have recently run ahead of actual cash, which we track closely.
The price is expensive. You pay 100.7× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 28% yearly growth; analysts expect 32%. The price, in other words, assumes less than the experts do.
The trajectory is solid and the balance sheet is sturdy. The company scores 14/20 on our value-creation score: strong value creator.
What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202364
64
2023202420252026
All-time high
91
Jan 2025
All-time low
64
Jun 2026
Average rank
72
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
15
16
17
28
Price/Earnings
7
15
20
12
Price/Book
27
27
26
28
Dividend Yield
1
1
1
1
Value (overall)
6
7
8
11
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.